Top Experts Bet Big On Pharma Stocks: How U.S. Recovery Fuels The Surge?

Pharma Stocks Soar to New Highs: Is There More Upside or Are They Overvalued? Pharma stocks have been on an impressive rally, hitting new heights consistently over the past several days. But are these stocks overvalued, or is there still room for growth? Market veteran Sunil Subramanian believes there are still promising opportunities for investors. He explains that, much like the IT sector, the recovery in the U.S. economy—one of the largest markets for Indian pharma companies—is fuelling this surge. He also predicts that Indian pharma firms will continue to lead the market for the next few years, though growth could be delayed depending upon how U.S. economy grows ahead. However, Sunil Subramanian remains optimistic, expecting a U.S. rebound within a year. Within the pharma sector, domestic diagnostics and hospitals are set to bolster the overall growth story. On the technical front, market expert Raghvendra Singh also sees strong potential in pharma stocks. He highlights Sun Pharma and Aurobindo Pharma, predicting that Aurobindo could reach ₹1,700-₹1,800 and Sun Pharma could climb to ₹2,000 levels. Additionally, Raghvendra Singh shares his insights on midcap pharma firm Gufic BioScience, forecasting a short-term target of ₹425-₹430 and a potential rise to ₹465-₹500 within 2-3 months, recommending it as a buy.